


# Correlation

European Network  
Social Inclusion & Health

From Research to Practice  
Examples from European projects

Eberhard Schatz  
Project Coordinator





# Correlation

European Network  
Social Inclusion & Health

- > European network since 2004
- > Access to health and social services for marginalised groups
- > Financed 2004 – 2013 by EC, DG Sante
- > More than 180 partners in all European countries

## Targetgroups and members:

service provider

researcher

Peers and community members

policy and decision makers



## General objectives

Facilitate **exchange** of information, experience and skills between health and social service providers, policy makers, researchers and community members

Strengthen **capacities** of health and social service providers, policy makers, researchers and community members

Contribute to evidence-based **policy making** in the field of BBID





# Does it make sense? **SIT** outreach on the internet

**E-Health Policy Paper**

Jaana Kauppinen, Pro tukiopiste

## Greater Meaningful Involvement

of People Who Use Drugs

in 7 Key Principles and 18 Examples of Good Practice

## POLICY BRIEF ON HEPATITIS C INFECTION AMONG INJECTING DRUG USERS

Xavier Alajó Riera, Catalunya Ministry of Health, Programme on Substance Abuse  
Eberhard Scharf, Correlation Network  
Dasha Osharet, Eurasian Harm Reduction Network

Editor: Jason Farrell, Harm Reduction Consulting Services, Inc.

## Meaningful peer involvement among marginalised groups

**Correlation Policy Brief**

Katrin Schiffer, Correlation Network

### Effective Evaluation An introduction for grass-root organisations



**Introduction**

Correlation Network is pleased to present this new publication, 'Effective Evaluation: An introduction for grass-root organisations'. The publication is a result of a project funded by the European Union, which aimed to develop and disseminate good practice examples of effective evaluation in the field of social inclusion and health.

## Outreach and early intervention among young people at risk

**Correlation Policy Brief**

Anniken Sand, Competence Centre City of Oslo



EU 28 survey and inventory

RAR — identify and describe harmful patterns

Implementation — targeted pilot interventions

Training — multiplier trainings based on results

Toolbox — build best practice guidance, resource centre

# Hep C Initiative concept and results

DPIP 2013

hepc

European Initiative  
Hepatitis C and Drug Use

initiative







# Why?

## Barriers to testing and treatment:

- Health systemic/political level
- Service provider level
- Community and patient level




# How?

Research:

Hepatitis C testing and treatment barriers among active drug users in 4 European cities




# Result



- High uptake of HCV antibody testing among clients of low-threshold services
- Main motive is that drug users want to know their status
- Infections with HCV are highly prevalent (77.5%)
- Treatment uptake is low with 33 drug users out of 179 who were anti HCV positive
- Main barriers to treatment:
  - Staff did not recommend or offer HCV treatment
  - Drug users fear side effects of medication
  - Resources to increase treatment uptake
- Good information on HCV and treatment – drug + health services and physicians have a key role
- Additional support provided to patients by local drug service
- Revision of national/ regional guidelines /recommendations for HCV treatment




# How ? Capacity Building



- Peer Training Manual
- 6 modules
  - Module 1: Understanding
  - Module 2: HCV prevention
  - Module 3: HCV testing and diagnosis
  - Module 4: HCV treatment
  - Module 5: Living with HCV
  - Module 6: HCV advocacy and action planning



# What happened after Porto?



*"I have lobbied for a special representative for HCV co-infection in the board of the Dutch association of people living with HIV. And I have become a liason at my local hospital for people with co-infection."*

*Joost Brantas, The Netherlands*

*through quitting with injecting."*

*Dirk Schaeffer, Germany*



# What happened after Porto?



*"We have started with a range of activities:*

*"Together with the local harm reduction  
"In UK harm reduction services including HCV services are under pressure of re-tendering, budget cuts and payment by results against rehab and recovery. I wrote to the Lancet and BMJ to address my concern."*

*Steve Freen, England and other people who are interested attended the seminar.*

*And personally, I'm starting with my personal treatment as well..."*



# What happened after Porto?

*“Together with the Greek Association of Patients with a Liver Disease (Prometheus) we organised a public awareness campaign with a giant and mobile yellow letter C. We offered information and a rapid test for those who wanted to. The complimentary Facebook-page where people could upload their personal pictures also was a great success. The action started in Athens and traveled to other cities later on. The action has been documented on youtube: [www.youtube.com/watch?v=iJ8kSr79O7w](http://www.youtube.com/watch?v=iJ8kSr79O7w)”*

Hepatitis C awareness campaign in Greece

Efi Kokini, Greece University of Porto, Public Health Institute (ISPA)



# How? Capacity building:

The resource centre collects information and data about hepatitis and drug use.

You are invited to send us your links and files to be presented here.

resource centre:

> 250 entries


> 19 categories

- Alternative Treatments
- Burden & Prevalence of HCV
- Cost Effectiveness of HCV Prevention & Treatment
- HCV & Drug Use
- HCV & Sex
- HCV Epidemiological Data
- HCV History & Facts
- HCV in Prisons
- HCV Prevention Interventions
- HCV Related Books
- HCV Research Including IDUs
- HCV Testing Guidelines
- HCV Treatment & Prevention
- HCV Treatment Side Effects & Interactions
- HIV/HCV Co-Infection
- Integrating HCV Services
- Living with HCV
- Peer and Patient Support
- Policy Guidelines and Recommendations



# Result

# BMC reader



www.biomedcentral.com/bmcinfectdis/supplements/14/S6

Log on

BioMed Central Journals Gateways

BMC Infectious Diseases IMPACT FACTOR 2.56

Search this journal for Go

Advanced search

Home Articles Authors Reviewers About this journal My BMC Infectious Diseases

### Articles

All articles Sections Most popular Archive Supplements Article collections

BMC Infectious Diseases publishes selected collections of research articles, conference proceedings, reviews and reports as supplements, which are free to access online. All articles published in supplements are subject to peer review; meeting abstracts undergo review and selection by the conference. [Find out more](#) about publishing a supplement with BioMed Central.

## Volume 14 Supplement 6

### Viral Hepatitis and Drug Use in Europe

Research and Commentaries  
Edited by Jeffrey V Lazarus and Kevin A Fenton  
Read the [blog](#) related to this supplement.

This publication has been produced with the financial support of the Drug Prevention and Information Programme (DPIP) of the European Union. The contents of this publication are the sole responsibility of the authors and can in no way be taken to reflect the view of the European Commission. The publication charges for this supplement were funded by AbbVie as an unrestricted grant to Rigshospitalet, the University of Copenhagen, Denmark. AbbVie further co-funded the printing of the supplement. The peer review process was overseen by the Supplement Editors in accordance with BioMed Central's peer review guidelines for supplements. The Supplement Editors declare that they have no competing interests.

**Introduction** [Open Access](#)  
**Hepatitis – a devastating epidemic in Europe**  
Jeffrey V Lazarus, Kevin A Fenton  
*BMC Infectious Diseases* 2014, **14**(Suppl 6):S1 (19 September 2014)  
[Full text](#) | [PDF](#) | [PubMed](#)

**Commentary** [Open Access](#)  
**No strategy to meet the HCV epidemic**  
Olav Dalgard, Stefan Mauss  
*BMC Infectious Diseases* 2014, **14**(Suppl 6):S2 (19 September 2014)  
[Full text](#) | [PDF](#) | [PubMed](#)

**Commentary** [Open Access](#) **Highly accessed**  
**Improved hepatitis C screening and treatment in people who inject drugs should be a priority in Europe**  
Achim Kautz, Liliyana Chavdarova, Margaret Walker  
*BMC Infectious Diseases* 2014, **14**(Suppl 6):S3 (19 September 2014)  
[Full text](#) | [PDF](#) | [PubMed](#)

**Commentary** [Open Access](#)  
**Ending the mass criminalisation of people who use drugs: a necessary component of the public health response to hepatitis C**  
Chris Ford, Juliet Bressan

Submit a manuscript  
Register  
Sign up for article alerts  
Contact us  
Follow us on Twitter

Explore journal


- Editorial Board
- Instructions for authors
- FAQ



# Why do we need a new hepatology journal?

Today, World Hepatitis Day, is a time for celebrating all forms of progress in combating this group of diseases. It's also an opportunity to ask what more needs to be done. Our new journal *Hepatology, Medicine and Policy (HMAP)* aims to spur a global dialogue around this question, and here Editor-in-Chief Jeffrey V. Lazarus tells us why the journal fills an important gap in hepatology research.

Jeffrey V. Lazarus 28 Jul 2015



Jeffrey V. Lazarus

Prof Lazarus, the Editor in Chief of *Hepatology, Medicine and Policy*, is a senior researcher based at the Centre for Health and Infectious Disease Research (CHIP) and WHO Collaborating Centre on HIV and Viral Hepatitis at Rigshospitalet, the University of Copenhagen. He is also a professor at the Lithuanian University of Health Sciences, Medical Academy, and serves as the Board Chair of AFEW and as a section editor of *BMC Health Services Research*.



BioMed Central (BMC) open-access, peer-reviewed journal entitled *Hepatology, Medicine and Policy*: <http://www.hmap.biomedcentral.com/>.

**Scope:** *Hepatology, Medicine and Policy* considers articles on liver disorders, including viral and non-viral hepatitis, with a focus on policy at all levels from clinical to health services research and public health.



# How?



Policy: overall advocacy goal is to Influence HCV policies and advocate for the development and implementation of evidence-based HCV strategies at the European and National levels.

- increase knowledge about HCV European and national policy guidelines
- raise awareness on the gap between the needs and the political responses for HCV in Europe
- increase the sustainable involvement, strengthening and participation of Civil Society on HCV policies decision making process

# Result

## Manifesto

- Scale up evidence based harm reduction services
- Access to HCV testing, treatment and care services
- Access to affordable HCV treatments
- Decriminalisation of people who use drugs
- Meaningful involvement of high risk communities
- Improved HCV and health Literacy
- Effective targeted HCV strategies and action plans



# What's next?

Develop the initiative to a sustainable platform



# What's next?



**New project in the EC DG Sante health programme???**

- 21 partner + 20 collaborating partner:  
Universities, Health Institutes, Community Organisations, NGO's, Networks, policy maker





# From Research to Practice



# Conclusion

## **Research is indispensable for good practice implementations and policy**

- Research outcomes need to be better connected to practice and policy
- Researcher need to listen to the needs of community and field workers
- Community need to be involved in designing and implementing research
- Community and HR organisations need to be equal partners
- We know a lot, the political will is missing

## **We need more focus on evidence to action**



Please find out more at [www.hepatitis-c-initiative.eu](http://www.hepatitis-c-initiative.eu)  
eschatz@correlation-net.org

# Thank you.

